Posted by Michael Wonder on 02 Nov 2023
Nectero Medical granted breakthrough therapy designation for the Nectero EAST system to treat infrarenal AAA
1 November 2023 - Phase 2/3 clinical trial to initiate enrolment in Q4, 2023.
Nectero Medical today announced that the US FDA has granted breakthrough therapy designation for the Nectero Endovascular Aneurysm Stabilisation Treatment (Nectero EAST) system to treat patients with infrarenal abdominal aortic aneurysm, maximum diameter 3.5 – 5.0 cm.
